



GRI Standards

GRI is an international independent standards organization that helps business, governments, and other organizations understand and communicate their impacts on various issues. We have applied the GRI Sustainability Reporting Standards as an identification and cross-reference tool to make meaningful data accessible to our stakeholders.

Statement of use

United Therapeutics has reported the information cited in this GRI content index for the period January 1, 2022 through December 31, 2022 with reference to the GRI Standards.

GRI 1 used

GRI 1: Foundation 2021

DISCLOSURE

LOCATION

GRI 2: General Disclosures 2021

2-1 Organizational details

United Therapeutics Corporation is a publicly-traded (Nasdaq: UTHR), public benefit corporation incorporated in Delaware.

Co-headquarters at Silver Spring, Maryland and Research Triangle Park, North Carolina

[2023 Report: Who We Are \(pgs. 5-12\)](#)

[2022 Form 10-K: Item 1. Business – Overview \(pg. 3\), Item 2. Properties \(pg. 44\)](#)

[Corporate Website: Our Company](#)

2-2 Entities included in the organization's sustainability reporting

[2022 Form 10-K: Exhibit 21](#)



DISCLOSURE

LOCATION

2-3 Reporting period, frequency and contact point

Reporting period: January 1, 2022 through December 31, 2022, our fiscal 2022 year. In some cases, we include data and information about programs and activities relevant to our ESG priorities that occurred in the 2023 fiscal year, as noted.

Reporting cycle: Annual

Publication date of this Report: September 12, 2023

Contact point for questions regarding the report: ir@unither.com

2-4 Restatements of information

N/A

2-5 External assurance

N/A

2-6 Activities, value chain and other business relationships

United Therapeutics Corporation is the first publicly traded biotech or pharmaceutical company to take the form of a public benefit corporation. Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs. At the same time, we seek to provide our shareholders with superior financial performance and our communities with earth-sensitive energy utilization.

[2023 Report: Who We Are \(pgs. 5-12\)](#)

[2022 Form 10-K: Item 1. Business \(pgs. 3-30\)](#)

[Corporate Website: Our Company](#)

2-7 Employees

[2023 Report: 2022 Unitherians at a Glance \(pg. 36\)](#)

2-8 Workers who are not employees

Contingent workers make up 5.3% of the workforce, and we do not experience seasonal variations of our workforce.



DISCLOSURE

LOCATION

2-9 Governance structure and composition

2023 Report: Governance (pgs. 67-70)

2023 Proxy Statement: Our Corporate Governance (pgs. 17-36)

Corporate Website: Corporate Governance

2-10 Nomination and selection of the highest governance body

2023 Proxy Statement: Selecting Directors (pgs. 17-21)

2-11 Chair of the highest governance body

2023 Proxy Statement: Board Structure (pg. 30)

2-12 Role of the highest governance body in overseeing the management of impacts

2023 Report: ESG and PBC Governance (pgs. 67-68)

Proxy Statement: Board Roles and Responsibilities (pgs. 33-34)

Corporate Website: Audit, Compensation and Nominating and Governance Committee Charters

2-13 Delegation of responsibility for managing impacts

2023 Report: ESG and PBC Governance (pgs. 67-68), Our Patient Safety Operations (pg. 24), Our Quality Operations (pg. 26), Diversity, Equity, and Inclusion (pgs. 40-42), Our Approach to Climate (pgs. 50-51), Our Compliance Model (pg. 71), Data Privacy and Security (pgs. 74-75), Enterprise Risk Management and Organizational Resilience (pgs. 76-78)

2-14 Role of the highest governance body in sustainability reporting

2023 Report: ESG and PBC Governance (pgs. 67-68)

2-15 Conflicts of interest

2023 Report: Ethics and Compliance (pgs. 70-73)

2023 Proxy Statement: Selecting Directors (pgs. 17-19)

Corporate Website: Code of Conduct



DISCLOSURE

LOCATION

2-16 Communication of critical concerns

2023 Report: Ethics and Compliance (pgs. 70-73)

2023 Proxy Statement: Shareholder Communication with Directors (pg. 36)

Corporate Website: Code of Conduct

2-17 Collective knowledge of the highest governance body

2023 Proxy Statement: Board of Directors and Nominees (pgs. 22-29), Board Education (pg. 36)

2-18 Evaluation of the performance of the highest governance body

2023 Proxy Statement: Selecting Directors (pgs. 17-20)

Corporate Website: Nominating and Governance Committee Charter and Corporate Governance Guidelines

2-19 Remuneration policies

2023 Proxy Statement: Non-Employee Director Compensation (pgs. 37-39), Executive Compensation (pgs. 40-59)

2-20 Process to determine remuneration

2023 Proxy Statement: Non-Employee Director Compensation (pgs. 37-39), Executive Compensation (pgs. 40-59)

2-21 Annual total compensation ratio

2023 Proxy Statement: Pay Ratio (pg. 71)

2-22 Statement on sustainable development strategy

2023 Report: A Message from Our CEO (pg. 3), Our Purpose and Progress (pgs. 9-11), A Message from Our Chief Medical Officer (pg. 14), A Message from Our Chief People Officer (pg. 35), A Message from Our General Counsel (pg. 48)

2-23 Policy commitments

2023 Report: Our Purpose and Progress (pgs. 9-11), Where our PBC Goals and ESG Priorities Meet (p. 12), Ethics and Compliance (pgs. 70-73)

Corporate Website: Corporate Governance

2-24 Embedding policy commitments

2023 Report: Our Purpose and Progress (pgs. 9-11), Where our PBC Goals and ESG Priorities Meet (pg. 12), 2022 Innovation at a Glance (p. 15), Clinical Trials (pg. 17), Product Quality and Patient Safety (pgs. 22-28), 2022 Patient Support at a Glance (pg. 29), 2022 Reliable Supply at a Glance (pg. 33), 2022 Unitherians at a Glance (pgs. 36-37), 2022 Environmental Stewardship at a Glance (pg. 49), 2022 Community Impacts at a Glance (pg. 58), ESG and PBC Governance (pgs. 67-68), Ethics and Compliance (pgs. 70-73)



DISCLOSURE

LOCATION

2-25 Processes to remediate negative impacts	2023 Report: Environmental Stewardship (pgs. 49-57), Clinical Trials (pg. 17), Product Quality and Patient Safety (pgs. 22-28), Responsible Business Practices (pgs. 67-78)
2-26 Mechanisms for seeking advice and raising concerns	2023 Report: Ethics and Compliance (pgs. 70-73)
2-27 Compliance with laws and regulations	2023 Report: Ethics and Compliance (pgs. 70-73) 2022 Form 10-K: Item 1. Business – Government Regulation and Environmental Matters (pgs. 17-29), Item 1A. Risk Factors (pgs. 32-43), Item 8. Financial Statements and Supplementary Data – Note 14. Litigation (pgs. F-32-F-35) Corporate Website: Code of Conduct, UK Tax Strategy
2-28 Membership associations	We maintain strategic memberships in local, regional, national, and international associations and/or organizations unique to biopharma, environmental, regional, and community-oriented matters.
2-29 Approach to stakeholder engagement	Shareholder engagement is a core part of our corporate governance process, and includes direct involvement from our Board. Engagement with other relevant stakeholders occurs throughout our organization at the business unit level. 2023 Report: Our PBC Objectives and ESG Priority Issues (pg. 12), About This Report and Stakeholder Engagement (pgs. 80-81)
2-30 Collective bargaining agreements	None
GRI 3: Material Topics 2021	
3-1 Process to determine material topics	2023 Report: Where our PBC Goals and ESG Priorities Meet (pg. 12), About This Report and Stakeholder Engagement (pgs. 80-81)
3-2 List of material topics	2023 Report: Where our PBC Goals and ESG Priorities Meet (pg. 12)
3-3 Management of material topics	2023 Report: Our Purpose and Progress (pgs. 9-11), Where our PBC Goals and ESG Priorities Meet (pg. 12), ESG and PBC Governance (pgs. 67-68)



DISCLOSURE

LOCATION

GRI 201: Economic Performance 2016

201-1 Direct economic value generated and distributed

[2023 Report: 2022 Year in Review \(pg. 7\)](#)

201-2 Financial implications and other risks and opportunities due to climate change

Given the significant threat of climate change, United Therapeutics has taken aggressive and groundbreaking steps to diminish its climate impact.

[2023 Report: Our Approach to Climate \(pgs. 50-51\), Our Organizational Resilience Program \(pg. 77\)](#)

201-3 Defined benefit plan obligations and other retirement plans

2022 Form 10-K: Item 8. Financial Statements and Supplementary Data – Note Employee Benefit Plans. Litigation (pgs. F-28-F-30)

As of December 31, 2022, we had 96.9% participation in our U.S. 401(k) plan.

GRI 202: Market Presence 2016

202-1 Ratios of standard entry level wage by gender compared to local minimum wage

[2023 Report: Our Culture and Benefits Program \(pgs. 38-39\)](#)

We pay all employees a minimum base salary of \$62,500 (with a total of approximately \$75,000 per year including each employee’s bonus opportunity), well above all applicable minimum wage levels.

202-2 Proportion of senior management hired from the local community

Not tracked

GRI 203: Indirect Economic Impacts 2016

203-1 Infrastructure investments and services supported

[2023 Report: No Patient Left Behind \(pgs. 29-33\), Humankind \(pgs. 48-65\)](#)

203-2 Significant indirect economic impacts

[2023 Report: No Patient Left Behind \(pgs. 29-33\), Humankind \(pgs. 48-65\)](#)



DISCLOSURE

LOCATION

GRI 204: Procurement Practices 2016

204-1 Proportion of spending on local suppliers

We track our spend on all of our major projects, with an emphasis on selecting vendors and service providers located in the county or state where the project is located. For example, most of the 600 pre-qualified GMP suppliers are based in the North America.

GRI 205: Anti-corruption 2016

205-1 Operations assessed for risks related to corruption

[2023 Report: Ethics and Compliance \(pg. 70\)](#)

205-2 Communication and training about anti-corruption policies and procedures

[2023 Report: Ethics and Compliance \(pg. 70\)](#)

205-3 Confirmed incidents of corruption and actions taken

None

GRI 206: Anti-competitive Behavior 2016

206-1 Legal actions for anti-competitive behavior, anti-trust, and monopoly practices

[2022 Form 10-K: Item 8. Financial Statements and Supplementary Data – Note 14. Litigation \(pgs. F-32-F-35\)](#)

GRI 301: Materials 2016

301-1 Materials used by weight or volume

Within the boundaries defined by patient safety and regulatory compliance, United Therapeutics works to minimize the footprint we leave with raw materials consumption in our operations.

301-3 Reclaimed products and their packaging materials

We participate in the Pharmaceutical Product Stewardship Work Group (PPSWG) MyOldMeds industry takeback program.



DISCLOSURE

LOCATION

GRI 302: Energy 2016

302-1 Energy consumption within the organization	<p>We are in the process of validating all environmental data, closing certain data gaps, and creating an assurance-ready set of data collection and management procedures with the assistance of an audit firm.</p> <p>See Our Approach to Climate, which relies on energy data, (pgs. 50-51)</p>
302-2 Energy consumption outside of the organization	<p>We have not evaluated our Scope 3 category energy sources and emissions.</p>
302-3 Energy intensity	<p>We are in the process of validating all environmental data, closing certain data gaps, and creating an assurance-ready set of data collection and management procedures with the assistance of an audit firm.</p> <p>See Our Approach to Climate, which relies on energy data, (pgs. 50-51)</p>
302-4 Reduction of energy consumption	<p>We are in the process of validating all environmental data, closing certain data gaps, and creating an assurance-ready set of data collection and management procedures with the assistance of an audit firm.</p> <p>See Our Approach to Climate, which relies on energy data, (pgs. 50-51)</p>

GRI 303: Water and Effluents 2018

303-1 Interactions with water as a shared resource	<p>2023 Report: Water Management (pg. 56)</p>
303-2 Management of water discharge-related impacts	<p>Sites that have wastewater discharge permits comply with water quality standards for the quality of effluent discharge established by the conditions contained in the permits.</p>
303-3 Water withdrawal	<p>We are integrating water and waste data into our centralized environmental data management system to enable future comprehensive reporting.</p>
303-4 Water discharge	<p>Sites that have wastewater discharge permits comply with water quality standards for the quality of effluent discharge established by the conditions contained in the permits.</p>
303-5 Water consumption	<p>We are integrating water and waste data into our centralized environmental data management system to enable future comprehensive reporting.</p>



DISCLOSURE

LOCATION

GRI 305: Emissions 2016

305-1 Direct (Scope 1) GHG emissions	2023 Report: See Our Approach to Climate (pg. 50)
305-2 Energy indirect (Scope 2) GHG emissions	2023 Report: See Our Approach to Climate (pg. 50)
305-3 Other indirect (Scope 3) GHG emissions	2023 Report: See Our Approach to Climate (pg. 50)
305-4 GHG emissions intensity	2023 Report: See Our Approach to Climate (pg. 50)
305-5 Reduction of GHG emissions	2023 Report: See Our Approach to Climate (pg. 50)

GRI 306: Waste 2020

306-1 Waste generation and significant waste-related impacts	2023 Report: Responsible Waste Management (pg. 56)
306-2 Management of significant waste-related impacts	2023 Report: Responsible Waste Management (pg. 56)
306-3 Waste generated	We are integrating water and waste data into our centralized environmental data management system to enable future comprehensive reporting.
306-4 Waste diverted from disposal	We are integrating water and waste data into our centralized environmental data management system to enable future comprehensive reporting.
306-5 Waste directed to disposal	We are integrating water and waste data into our centralized environmental data management system to enable future comprehensive reporting.



DISCLOSURE

LOCATION

GRI 401: Employment 2016

401-1 New employee hires and employee turnover

[2023 Report: 2022 Unitherians at a Glance \(pg. 36\)](#)

401-2 Benefits provided to full-time employees that are not provided to temporary or part-time employees

[2023 Report: Our Culture and Benefits Program \(pgs. 38-39\)](#)

In 2022, we began to provide access to medical, dental, and vision benefits to part-time Unitherians.

401-3 Parental leave

[2023 Report: 2022 Unitherians at a Glance \(pg. 36\)](#)

All full-time employees are eligible for parental leave.

GRI 403: Occupational Health and Safety 2018

403-1 Occupational health and safety management system

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

403-2 Hazard identification, risk assessment, and incident investigation

Hazard identification, risk assessments, and incident investigations are used on a routine and non-routine basis through compliance initiatives, loss profile reviews, new process and engineering reviews, and incident, near miss and hazard analysis reporting. Employees are encouraged to report work-related hazards and hazardous situations to their management and through other appropriate channels.

403-3 Occupational health services

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

403-4 Worker participation, consultation, and communication on occupational health and safety

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

We collaborate with employees and leadership through collective group forums to develop practices that directly improve our occupational health and safety performance. Group forums meet routinely to help facilitate collaboration and successful employee involvement.



DISCLOSURE

LOCATION

403-5 Worker training on occupational health and safety

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

Training needs have been assessed by EHSS, and a comprehensive training curriculum has been developed and assigned to all manufacturing and laboratory workers. This training is compliance-based and specific to work-related hazards and potentially hazardous activities in each worker's job function. Training is delivered during work hours in a hybrid format, both online in multiple languages through Universe and in-person in our state-of-the-art training rooms.

403-6 Promotion of worker health

[2023 Report: Our Culture and Benefits Program \(pgs. 38-39\), Safe and Healthy Workplaces \(pgs. 45-46\)](#)

403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

The prevention and mitigation of occupational health and safety impacts that are directly linked to our operations, products, or services by business relationships and the related hazards and risks are managed by line management. For example, safety information, engineering controls, and PPE relating to hazardous materials, including pharmaceutical compounds and pharmaceutical intermediate materials, are available to train and protect workers from hazards associated with our operations.

403-8 Workers covered by an occupational health and safety management system

[2023 Report: Safe and Healthy Workplaces \(pgs. 45-46\)](#)

403-9 Work-related injuries

[2023 Report: 2022 Unitherians at a Glance \(pg. 36\)](#)

403-10 Work-related ill health

[2023 Report: 2022 Unitherians at a Glance \(pg. 36\)](#)



DISCLOSURE

LOCATION

GRI 404: Training and Education 2016

404-1 Average hours of training per year per employee

2023 Report: 2022 Unitherians at a Glance (pg. 36); Our Culture and Benefits Program (pg. 38)

404-2 Programs for upgrading employee skills and transition assistance programs

2023 Report: 2022 Unitherians at a Glance (pg. 36); Our Culture and Benefits Program (pg. 38), The Unitherian Journey (pgs. 43 - 44)

404-3 Percentage of employees receiving regular performance and career development reviews

2023 Report: 2022 Unitherians at a Glance (pg. 36); Our Culture and Benefits Program (pg. 38)

GRI 405: Diversity and Equal Opportunity 2016

405-1 Diversity of governance bodies and employees

2023 Report: 2022 Unitherians at a Glance (pg. 36)

GRI 413: Local Communities 2016

413-1 Operations with local community engagement, impact assessments, and development programs

2023 Report: Our Communities (pgs. 58-65)

GRI 416: Customer Health and Safety 2016

416-1 Assessment of the health and safety impacts of product and service categories

2023 Report: Product Quality and Safety (pgs. 22-28)

416-2 Incidents of non-compliance concerning the health and safety impacts of products and services

FDA website



DISCLOSURE

LOCATION

GRI 417: Marketing and Labeling 2016

417-1 Requirements for product and service information and labeling

2022 Form 10-K: Item 1. Business – Government Regulation (pgs. 17-28)

417-2 Incidents of non-compliance concerning product and service information and labeling

None

417-3 Incidents of non-compliance concerning marketing communications

None

GRI 418: Customer Privacy 2016

418-1 Substantiated complaints concerning breaches of customer privacy and losses of customer data

None



SASB Topics

SASB is an independent, private sector standards-setting organization whose mission is to help businesses around the world identify, manage, and report on the sustainability topics that SASB believes matter most to investors. We have considered the industry standards (as defined by SASB’s Industry Classification System) for the Biotechnology and Pharmaceuticals Sector, and the table below represents some topics that we believe are relevant to our company and that are discussed in our 2023 Report. In certain instances, and as noted below, a specific SASB topic may be discussed generally in our 2023 Report but we do not currently track or report progress on the corresponding SASB metrics.

SASB Topic	Code	Accounting Metric	Explanation or Location
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion of, by world region, management process for ensuring quality and patient safety during clinical trials	2023 Report: Our Patient Safety Operations (pgs. 24-25)
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	None
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	None
Access to Medicine	C-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	2023 Report: Our Purpose and Progress (pgs. 9-11), Our PBC Objectives and ESG Priority Issues (pg. 12), Innovation (pgs. 15-19), Patient Support (pgs. 29-32) While not listed as a company in scope for the 2023 Access to Medicine Index, we are deeply committed to increasing access to our medicines. Two of our Initial PBC goals – Address Unserved Needs and No Patient Left Behind – demonstrate this commitment. In addition, our current commercial and therapeutic footprint does not cover any priority countries or priority diseases listed in the Access to Medicine Index.
	C-BP-240.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	We have no products on the WHO List of Prequalified Medicinal Products because our core therapeutic areas – pulmonary hypertension and pediatric neuroblastoma – are not in the therapeutic scope of the WHO List of Prequalified Medicinal Products.



SASB Topic	Code	Accounting Metric	Explanation or Location
Affordability and Pricing	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	2023 Report: Pricing (pg. 32) . Additional detail on this metric would potentially reveal competitive information given our small portfolio of five FDA-approved medicines as compared to larger pharmaceutical companies. We do not control pricing over our medicine Adcirca.
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	2023 Report: Pricing (pg. 32) . Additional detail on this metric would potentially reveal competitive information given our small portfolio of five FDA-approved medicines as compared to larger pharmaceutical companies. We do not control pricing over our medicine Adcirca.
Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration’s (FDA) MedWatch Safety Alerts for Human Medical Products database	Please visit the FDA FAERS MedWatch website for more information.
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Please visit the FDA FAERS MedWatch website for more information.
	HC-BP-250a.3	Number of recalls issued, total units recalled	None
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	None
Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	2023 Report: Anti-Counterfeiting and Package Serialization (pg. 25)
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	None



SASB Topic	Code	Accounting Metric	Explanation or Location
Ethical Marketing	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	None
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	Corporate Website: unither.com > Investors > Corporate Governance > Code of Conduct
Employee Recruitment, Development and Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	2023 Report: Our People (pp. 35-46)
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	2023 Report: 2022 Unitherians at a Glance (pg. 36)
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	UT is a member of Rx-360 international through which we supplement our own vendor audit program with Rx-360 audits, and we have sponsored Rx-360 audits.
Business Ethics	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	None
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	Corporate Website: unither.com > Investors > Corporate Governance > Code of Conduct
Activity Metrics	HC-BP-000.A	Number of patients treated	Refer to Our Purpose and Programs, 2022 progress (pg. 10)
	HC-BP-000.B	Number of drugs (1) in portfolio and (2) in R&D (Phases 1–3)	See our development programs on p. 16 ; see our pipeline at https://pipeline.unither.com/



TCFD Framework

The TCFD has developed a framework of recommendations to help public companies and other organizations more effectively disclose climate-related risks and opportunities through their existing reporting processes. The following table outlines our climate-related discussions in accordance with the TCFD framework.

TCFD Recommendation	Explanation or Location
<p>Governance Disclose the organization’s governance around climate-related risks and opportunities.</p>	<p>2023 Report: Our Approach to Climate (pgs. 50-51), ESG and PBC Governance (pgs. 67-68)</p>
<p>Strategy Disclose the actual and potential impacts of climate-related risks and opportunities on the organization’s businesses, strategy, and financial planning where such information is material.</p>	<p>2023 Report: A Message from Our General Counsel (pg. 48), Our Approach to Climate (pgs. 50-51)</p>
<p>Risk Management Disclose how the organization identifies, assesses, and manages climate-related risks.</p>	<p>2023 Report: Our Approach to Climate (pgs. 50-51), Enterprise Risk Management and Organizational Resilience (pgs. 76-78)</p>
<p>Metrics and Targets Disclose the metrics and targets used to assess and manage relevant climate-related risks and opportunities where such information is material.</p>	<p>We are in the process of validating all environmental data, closing certain data gaps, and creating an assurance-ready set of data collection and management procedures with the assistance of an audit firm; see Our Approach to Climate (pg. 50)</p>